Neuritek Therapeutics

Name

Neuritek Therapeutics

Legal name

Neuritek Therapeutics, Inc.

Website

https://neuritek.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Neuropsychiatric Therapeutics

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI)

Keywords

• PTSD therapeutics
• FAAH inhibitor development
• Clinical-stage biopharmaceutical
• GPCR-targeted therapeutics
• Neurology drug development

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Marketing channels1 record

Core offering

Neuritek Therapeutics is a clinical-stage biopharmaceutical company developing NRTK001, a first-in-class FAAH inhibitor designed to treat post-traumatic stress disorder (PTSD) by activating the body's own G-protein coupled receptors (GPCRs) to reduce anxious arousal. The program is built on more than a decade of proprietary PTSD research, and the Phase 1 trial has been successfully completed under an FDA-cleared IND with Phase 2 PTSD studies under preparation. The company targets PTSD subtypes with a mechanism-based approach intended to avoid the psychoactive side effects of psychedelic treatments.

Product overview

Neuritek Therapeutics is a biopharmaceutical company developing a single lead program, NRTK001, which is a first-in-class FAAH inhibitor treatment for Post-Traumatic Stress Disorder (PTSD). The company's therapeutic approach activates the body's own G-protein coupled receptors to enable resilience to stress. The company has completed Phase 1 trials and is preparing for Phase 2 studies in PTSD. The pipeline is built on 10 years of proprietary PTSD research and focuses on targeting PTSD subtypes rather than treating PTSD as a unitary disorder.

Differentiator

Problem solved

Functional benefit

Products and services

• NRTK001

Quantifiable outcome

• PTSD will develop in 20% of trauma survivors, with about 1 in 3 developing chronic PTSD
• +2 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Emerging players

• Compass Pathways: Compass Pathways is developing psilocybin therapy for treatment-resistant depression and PTSD, positioning it as a competing modality for next-generation mental health therapeutics. It overlaps with Neuritek on PTSD indication but differs via psychedelic mechanism.
• Praxis Precision Medicines: Praxis is a clinical-stage CNS biopharma applying precision medicine approaches to neurological and psychiatric disorders. Its biomarker-driven CNS development strategy parallels Neuritek's multi-modality biomarker approach.
• ATAI Life Sciences: ATAI is a clinical-stage mental health biopharma platform developing psychedelic and non-psychoactive compounds for depression, PTSD, and anxiety. Its multi-program mental health focus and clinical-stage profile make it a comparable emerging peer.
• Marinus Pharmaceuticals: Marinus is a clinical/commercial-stage CNS biopharma developing ganaxolone for seizure disorders and related neurological conditions. Its CNS specialty biopharma profile and clinical-stage orientation are comparable to Neuritek.
• Axsome Therapeutics: Axsome is a CNS-focused biopharma with approved products (Auvelity, Sunosi) and a development pipeline in depression and other CNS indications. Its clinical-to-commercial CNS trajectory and size profile are comparable to where Neuritek could evolve.

Broad incumbents

• Neurocrine Biosciences: Neurocrine is an established commercial CNS biopharma with marketed products across neurology and psychiatry. It serves as a reference for what a successful scaled CNS biopharma platform looks like and a potential strategic acquirer of pipeline assets.
• Otsuka Pharmaceutical: Otsuka has marketed CNS products including ABILIFY (aripiprazole), which is widely used in PTSD, and is active in CNS drug development. It represents a major incumbent with overlapping mental health therapeutic focus and potential strategic interest in novel PTSD mechanisms.
• Acadia Pharmaceuticals: Acadia is a commercial-stage CNS biopharma with approved products (e.g., NUPLAZID) in neuroscience, providing a comparable specialty CNS commercial and development profile. It represents an established reference point for the CNS biopharma business model.

Direct peers

• Tonix Pharmaceuticals: Tonix is developing TNX-102 SL (sublingual cyclobenzaprine) specifically for PTSD and is a clinical-stage CNS biopharma with similar indication focus and stage to Neuritek. It is the most directly comparable company given its single-program PTSD orientation.
• Bionomics: Bionomics is developing BNC210, a negative allosteric modulator of the alpha-7 nicotinic receptor, for PTSD and anxiety disorders. It is a direct clinical-stage peer sharing Neuritek's CNS mechanism-driven, single-indication focus on PTSD.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/neuritek
• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/neuritek-therapeutics-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neuritek Therapeutics